Literature DB >> 35861895

Successful Treatment of Primary Amoebic Meningoencephalitis Using a Novel Therapeutic Regimen Including Miltefosine and Voriconazole.

Dalila Y Martínez1,2, Fanny Bravo-Cossio3, María Del Carmen Valdivia-Tapia3, Nilton Yhuri Carreazo4, Alfonso M Cabello-Vilchez1,5.   

Abstract

The genus Naegleria consists of free-living amoebae widely distributed worldwide in soil and freshwater habitats. Primary amoebic meningoencephalitis (PAM) is an uncommon and most likely fatal disease. The incubation period is approximately 7 days. The first symptoms are headache, nasal congestion, fever, vomiting, stiff neck within 3-4 days after the first symptoms, confusion, abnormal behavior, seizures, loss of balance and body control, coma, and death. We describe the case of a child who presented with PAM due to Naegleria sp., fully recovered from the infection without apparent sequels after treatment with a regimen that included miltefosine and voriconazole.
© 2022. The Author(s) under exclusive licence to Witold Stefański Institute of Parasitology, Polish Academy of Sciences.

Entities:  

Keywords:  Central nervous system protozoal infections; Child; Miltefosine; Naegleria; Voriconazole

Mesh:

Substances:

Year:  2022        PMID: 35861895     DOI: 10.1007/s11686-022-00591-9

Source DB:  PubMed          Journal:  Acta Parasitol        ISSN: 1230-2821            Impact factor:   1.534


  13 in total

1.  Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis.

Authors:  W Matthew Linam; Mubbasheer Ahmed; Jennifer R Cope; Craig Chu; Govinda S Visvesvara; Alexandre J da Silva; Yvonne Qvarnstrom; Jerril Green
Journal:  Pediatrics       Date:  2015-02-09       Impact factor: 7.124

Review 2.  Naegleria fowleri: Sources of infection, pathophysiology, diagnosis, and management; a review.

Authors:  Muhammad Jahangeer; Zahed Mahmood; Naveed Munir; Umm-E-Amara Waraich; Imtiaz Mahmood Tahir; Muhammad Akram; Syed Muhammad Ali Shah; Ayesha Zulfqar; Rida Zainab
Journal:  Clin Exp Pharmacol Physiol       Date:  2019-11-15       Impact factor: 2.557

3.  Naegleria fowleri That Induces Primary Amoebic Meningoencephalitis: Rapid Diagnosis and Rare Case of Survival in a 12-Year-Old Caucasian Girl.

Authors:  Andrew L Dunn; Tameika Reed; Charlotte Stewart; Rebecca A Levy
Journal:  Lab Med       Date:  2016-03-15

4.  In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri.

Authors:  Frederick L Schuster; B Joseph Guglielmo; Govinda S Visvesvara
Journal:  J Eukaryot Microbiol       Date:  2006 Mar-Apr       Impact factor: 3.346

5.  Surviving Naegleria fowleri infections: A successful case report and novel therapeutic approach.

Authors:  Travis W Heggie; Thomas Küpper
Journal:  Travel Med Infect Dis       Date:  2016-12-22       Impact factor: 6.211

Review 6.  Naegleria fowleri: pathogenesis, diagnosis, and treatment options.

Authors:  Eddie Grace; Scott Asbill; Kris Virga
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

7.  Effect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleri.

Authors:  Jong-Hyun Kim; Suk-Yul Jung; Yang-Jin Lee; Kyoung-Ju Song; Daeho Kwon; Kyongmin Kim; Sun Park; Kyung-Il Im; Ho-Joon Shin
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

Review 8.  Is Naegleria fowleri an Emerging Parasite?

Authors:  Sutherland K Maciver; Jose E Piñero; Jacob Lorenzo-Morales
Journal:  Trends Parasitol       Date:  2019-11-18

Review 9.  Primary Amebic Meningoencephalitis: What Have We Learned in the Last 5 Years?

Authors:  Jennifer R Cope; Ibne K Ali
Journal:  Curr Infect Dis Rep       Date:  2016-09       Impact factor: 3.725

10.  Diagnosis, Clinical Course, and Treatment of Primary Amoebic Meningoencephalitis in the United States, 1937-2013.

Authors:  Linda G Capewell; Aaron M Harris; Jonathan S Yoder; Jennifer R Cope; Brittany A Eddy; Sharon L Roy; Govinda S Visvesvara; LeAnne M Fox; Michael J Beach
Journal:  J Pediatric Infect Dis Soc       Date:  2014-10-23       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.